An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201
An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
A safety extension study to evaluate the long-term safety of QGE031 in Chronic Spontaneous Urticaria patients
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria:
Exclusion Criteria:
Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria
Kamimashi-gun, Kumamoto 861-3101, Japan
Shinagawa Ku, Tokyo 141 8625, Japan